Introduction-2

[heading] EXAM QUESTIONS [/heading]

1- Cyclophosphamide is :

The correct answer is: A- alkylating agents

Cyclophosphamide is an alkylating agent that works by adding alkyl groups to DNA, leading to DNA cross-linking and cell death. It is commonly used in chemotherapy for various cancers and autoimmune conditions.

Cyclophosphamide is classified as a bifunctional alkylating agent within the nitrogen mustard therapeutic group. It functions by transferring alkyl groups to DNA bases, forming covalent bonds that result in interstrand and intrastrand cross-links, which ultimately inhibit DNA synthesis. Its full profile includes the following characteristics:

  • Pharmacological State: It is a prodrug that must be activated in the liver to become an active metabolite.
  • Cell Cycle Phase: It is a cell-cycle non-specific (CCNS) agent, meaning it exerts cytotoxic effects throughout any phase of the cell cycle and is effective against large, slowly growing tumors.
  • Emetogenic Risk: It ranges from Moderate Emetic Risk (MEC) at doses ≤1500 mg/m2 to High Emetic Risk (HEC) when used in doses >1500 mg/m2 or as part of the AC combination (anthracycline plus cyclophosphamide).
  • Primary Toxicities: Notable side effects include dose-limiting myelosuppression, alopecia, and hemorrhagic cystitis, which requires patients to maintain high fluid intake

Why not the others?

B- Enzyme inhibitors: Cyclophosphamide does not primarily work by inhibiting enzymes. Antitumor medications that are considered as enzyme inhibitors are:

  1. Topoisomerase Inhibitors

These agents prevent topoisomerase enzymes from cutting and re-ligating DNA strands, which normally prevents DNA from becoming tangled during replication.

2. Tyrosine Kinase Inhibitors (TKIs)

TKIs are small molecules or peptides that bind to the intracellular domains of cell-surface receptors. They function by inhibiting the ATP-binding site of tyrosine kinases, thereby blocking the signal transduction pathways that tell the cell to grow and multiply. Common medications in this category include:

3. Metabolic and Hormonal Enzyme Inhibitors

Several other antitumor drugs function by inhibiting specific enzymes necessary for cell survival or hormone production:

C- Antimicrotubules: This class includes drugs like taxanes (paclitaxel) and vinca alkaloids (vincristine), which disrupt microtubule function.
D- Antimetabolites: These are drugs like methotrexate or 5-fluorouracil, which interfere with DNA synthesis by mimicking metabolites.

2- Which drug requires both pre and post-medication with corticosteroids to prevent the fluid retention associated with it?

The correct answer is A- Docetaxel.

Explanation: Docetaxel is a taxane chemotherapy drug that requires both pre- and post-medication with corticosteroids (e.g., dexamethasone) to prevent:

  • Fluid retention (a common side effect of docetaxel).
  • Hypersensitivity reactions.

The other options are incorrect because:

Key Point: Docetaxel is uniquely associated with corticosteroid premedication to mitigate fluid retention.

Chemotherapy Premedication

Drug Main Toxicity Required Premedication Exam Pearl
Docetaxel Fluid retention, hypersensitivity Corticosteroids (pre + post) Steroids prevent capillary leak
Paclitaxel Hypersensitivity reactions Steroids + H1 + H2 blockers Cremophor solvent reaction
Cisplatin Severe nausea, nephrotoxicity Antiemetics + IV hydration Most emetogenic
Ifosfamide Hemorrhagic cystitis Mesna Mesna binds acrolein
Cyclophosphamide Hemorrhagic cystitis Mesna (high dose) Similar to ifosfamide
Bleomycin Pulmonary toxicity None (monitor PFTs) Lung fibrosis risk
Irinotecan Acute diarrhea Atropine Cholinergic syndrome
High-dose MTX Renal toxicity Leucovorin rescue “Rescue, not antidote.”
Anthracyclines Cardiotoxicity Dexrazoxane (selected cases) Dose-dependent
Vincristine Neurotoxicity None Peripheral neuropathy

3- Methotrexate antidote

The correct answer is A- Calcium folinate.

Methotrexate is classified as an antimetabolite and a folate antagonist. It works by competitively inhibiting the enzyme dihydrofolate reductase, which is essential for converting folic acid into the reduced folate metabolites needed for DNA synthesis. Because this process is critical for cell replication, high-dose Methotrexate therapy can be lethal to healthy cells unless a "rescue" agent is administered.
The Role of Calcium Folinate (Leucovorin)
Calcium folinate, also known as Leucovorin, is a reduced form of folate. Unlike standard folic acid, Calcium folinate does not require the dihydrofolate reductase enzyme to be functional; instead, it enters cells by passive diffusion and directly replenishes the supply of folate metabolites. This allows DNA synthesis to resume even in the presence of Methotrexate, effectively "rescuing" the patient from lethal toxicity.
Clinical Requirements for Rescue
Timing: Rescue must be initiated within 42 hours of the Methotrexate dose to be effective. It typically starts 12 to 42 hours after the infusion begins.
Monitoring: Treatment with Calcium folinate must continue until Methotrexate blood levels fall below 0.1 microM.
Influencing Factors: Factors such as "third space" fluids (e.g., ascites or pleural effusions) can slow the clearance of Methotrexate, requiring a prolonged rescue period.

Why Other Options Are Incorrect

B- Dexrazoxane:
This agent is used as an antidote for anthracycline (like doxorubicin) extravasation to prevent tissue damage. Dexrazoxane is primarily used as an intravenous antidote for anthracycline extravasation to prevent severe tissue damage. Regarding heart function, anthracyclines are known to cause chronic cardiomyopathies by generating oxygen-free radicals. Clinical management for this cardiotoxicity focuses on performing baseline MUGA scans to evaluate heart function and strictly enforcing cumulative lifetime dose limits. The probability of heart failure increases proportionally with the total amount of drug a patient receives over time. 

Pharmacological alternatives and emergency interventions for acute events:

  • Mitoxantrone: This agent is used as an alternative to traditional anthracyclines because it does not form oxygen-free radicals, which results in less cardiotoxicity.
  • Epinephrine: For acute cardiovascular collapse occurring during a severe infusion reaction, Epinephrine is the most important intervention and should be a standing order for nurses to administer.
  • Glucagon: This is indicated for patients experiencing cardiovascular collapse who are taking beta-blockers, as these medications can inhibit the therapeutic effect of epinephrine.
  • Vesicant Antidotes: While Dexrazoxane (Totect) and 99% DMSO are used as antidotes for anthracyclines, the sources specifically define their role as treatments for extravasation (leaking into surrounding tissue) rather than for managing systemic cardiotoxicity.
  • The primary clinical strategy for managing systemic cardiotoxicity remains prevention through baseline MUGA scans to evaluate heart function and strict adherence to cumulative lifetime dose limits to minimize the risk of congestive heart failure

C- Glucarpidase:
While used in modern clinical practice for non-clearing Methotrexate levels, it is not the primary rescue agent detailed in these specific foundational materials.
When Clearance is Impaired: The need for intensive clearance (the scenario where Glucarpidase is often employed) arises when the drug remains in the system too long. According to the sources, several factors can complicate this:

  • Third Space Fluids: Conditions such as ascites or pleural effusions can act as a reservoir, significantly slowing the clearance of Methotrexate and extending its terminal half-life.
  • Renal Damage: High-dose Methotrexate can cause renal tubular necrosis. To prevent this, protocols require vigorous hydration and the alkalinization of urine to ensure the drug is excreted safely

D- Hyaluronic acid (Hyaluronidase): 
Hyaluronidase is an enzyme used as a specialized antidote to manage the extravasation of Vinca alkaloids, such as vincristine, vinblastine, and vinorelbine. Because these chemotherapy agents are potent vesicants, they can cause severe tissue irritation or necrosis if they accidentally leak into the area surrounding the injection site. To treat this complication, clinical protocols recommend applying a warm pack to the affected area and administering 1 ml of hyaluronidase as an antidote

4-Drug causing conjunctivitis when used in high doses:

The correct answer is C- Cytarabine (Ara-C).

Cytarabine and Ocular Toxicity: High-dose Cytarabine (also known as ara-C) is defined as doses exceeding 1,000 mg/m². At these levels, the drug can cause chemical conjunctivitis. To prevent this complication, patients must receive:

  • Prophylactic Eye Drops: Dexamethasone 0.1% ophthalmic solution is administered every 4 to 6 hours.
  • Duration: The drops are typically continued for 7 days following the completion of high-dose therapy.

Other High-Dose Toxicities: Beyond conjunctivitis, high-dose Cytarabine therapy is associated with other severe side effects, including:

Context for Other Options

  • Doxorubicin: This anthracycline is primarily known for cardiotoxicity and causing red discoloration of the urine; it is not typically associated with conjunctivitis.
  • Gemcitabine: While it is a pyrimidine analogue similar to Cytarabine, it is used for solid tumors like pancreatic and lung cancer without the specific high-dose ocular requirements of ara-C.
  • Cladribine: This purine analogue is noted for an immunosuppressant effect on T-helper cells, often requiring prophylactic antibiotics, rather than ocular toxicity

Drug causing SIADH :

The correct answer is B- Vincristine.
Vincristine is a vinca alkaloid known to cause the syndrome of inappropriate antidiuretic hormone (SIADH),. Its other primary side effects include dose-limiting neurologic toxicity, constipation, and paralytic ileus. Notably, it rarely causes bone marrow suppression compared to other agents in its class, such as vinblastine. The other options are incorrect because they are associated with different primary toxicities:

Antiandrogens should be taken prior to treatment and in combination with which medication:

The correct answer is C- LHRH analogues.

  • Tumor Flare Prevention: Luteinizing Hormone-Releasing Hormone (LHRH) analogues, such as goserelin and leuprolide, cause an initial surge in LH, FSH, and ultimately testosterone when therapy begins.
  • Clinical Impact: This temporary surge can trigger a "disease flare," which often manifests as increased bone pain for the patient.
  • Prophylactic strategy: To mitigate this risk, clinical guidelines recommend administering antiandrogens (like flutamide or bicalutamide) prior to the first dose of an LHRH analogue and continuing them in combination,
  • Distinction from Antagonists: Unlike analogues, LHRH antagonists such as degarelix do not cause an initial testosterone surge and therefore do not require pre-treatment with antiandrogens to prevent flare symptoms

Why Not the Other Options?

Key Point: Antiandrogens + LHRH analogues are a standard combination in prostate cancer to prevent testosterone flare and maximize androgen suppression.

BK is a 56-year-old female with a history of breast cancer who comes into your pharmacy complaining of diarrhea, nausea & vomiting, increased thirst, and fatigue.

Which of the following symptoms are consistent with signs & symptoms of hypercalcemia?

  • A. Nausea & vomiting, increased thirst, fatigue (53%)
  • B. Fatigue, diarrhea, nausea & vomiting (21%)
  • C. Increased thirst, fatigue, diarrhea (11%)
  • D. Diarrhea, nausea & vomiting, increased thirst (15%)

The correct answer is A. Nausea & vomiting, increased thirst, fatigue.

Reasoning
Hypercalcemia is a common metabolic complication in cancer patients, particularly those with breast cancer or bone metastases. Its symptoms are consistent with general metabolic distress and renal impact:

  • Gastrointestinal Symptoms: Hypercalcemia is a recognized metabolic cause of nausea and vomiting.
  • Renal and Hydration Impact: It can lead to renal failure, which often manifests as increased thirst (polydipsia) and dehydration.
  • General Systemic Effects: Fatigue is a frequent presenting sign of both the underlying malignancy and the resulting electrolyte imbalance.

Why the other options are incorrect
Options B, C, and D are incorrect because they include diarrhea. Hypercalcemia typically causes constipation due to decreased smooth muscle tone. In contrast, diarrhea is more commonly associated with specific chemotherapy agents, such as irinotecan or 5-fluorouracil.